Navigation Links
WuXi PharmaTech Provides Update of 2010 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
Date:1/10/2011

SHANGHAI, Jan. 10, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, today announced that it will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 3:30 p.m. Pacific Standard Time and updated its 2010 financial guidance.  Based on preliminary, unaudited results, WuXi expects to slightly exceed the top end of its previous guidance for 2010 total net revenues of $330-333 million and to exceed year-over-year growth in 2010 non-GAAP operating income of 28-32%.  The company also expects to achieve the remainder of the 2010 financial guidance found in its third-quarter 2010 earnings release.

The company plans to report its audited fourth-quarter and full-year 2010 financial results and to provide 2011 financial guidance in March 2011.For more information, please contact:WuXi PharmaTech (Cayman) Inc.
Ronald Aldridge (for investors)
Director of Investor Relations
Tel: +1-201-585-2048
Email: ir@wuxiapptec.comStephanie Liu (for the media)
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.comForward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities <
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. WuXi PharmaTech Presents 2010 Life Science and Chemistry Awards
2. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting
3. WuXi PharmaTech Announces Third-Quarter 2010 Results
4. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
5. WuXi PharmaTech Schedules Third-Quarter 2010 Earnings Conference Call
6. Professor Steven V. Ley Speaks at WuXi PharmaTech
7. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
8. WuXi PharmaTech Announces Second-Quarter 2010 Results
9. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 Educating the community ... Association for the Advancement of Wound Care (AAWC), ... support from AAWC,s corporate partners, the Association provides ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ . ... pathway with links to various CME/CEU educational programs. ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
(Date:5/28/2015)... , May 28, 2015 The controversy ... )  in hysterectomies and myomectomies (procedures to remove uterine ... the FBI is investigating Johnson & Johnson,s Ethicon, ... of the devices. According to the report published ... th , the FBI is trying to determine ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III ... patients taking Afinitor® (everolimus) tablets* experienced a 50% ... subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors ... the largest prospective clinical trial to date in ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 3Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 4Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 5Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 6Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 7Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 8Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 9Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 10Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 11Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 12Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 13
(Date:5/30/2015)... 30, 2015 “ Milli the Snail ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... game that engages and educates children. , Interactive mobile games ... all the content and games they are playing are doing ...
(Date:5/29/2015)... “In the current environment of opiate ... we provide education that will help practitioners address ... from pain, within the boundaries of the guidelines ... rehabilitation medicine and President/Medical Director of the International ... A new flight of PAINWeekEnd Regional Conferences offers ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the “ ... now offers The Smartest Rheumatologist . The Smartest ... ranging from Fibromyalgia and Osteoporosis, to Arthritis and Gout. ... and Caroline Tredway, editorial head of The Smartest Doc ... on the physicians who participate. Says Tredway, “With so ...
(Date:5/29/2015)... The science of Follicular Unit Extraction (FUE) ... efficient methods of FUE hair transplantation have increased the amount ... most cutting edge hair transplant methods being used to great ... extracting hair from the beard to the scalp. , Most ... male pattern baldness. Beard hair has a life cycle, ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her ... else: God does no wrong. , It’s fitting, then, that ... is titled “God Does No Wrong.” It focuses on what ... tragedy. , “My story has a positive message about ... something productive, something healing,” Howse said. , “God Does No ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2
... THRM ), a leader in non-invasive tissue ... will present at the 2008 Maxim Group,Growth Conference. ... Time on Tuesday, October 7, 2008. Stephen J. ... the company,s business,strategy and historical financial results., ...
... Share Exchange Offer to the Holders of the Following Securities, ... JNJ, The K&N Value Select Corporation offers the holders of ... change into 1 share of,K&N Value Select Corp. - ISIN: CH0006603085 ... October 2008 and ends on 27th November,2008., K&N Value Select ...
... pleased to recognize the Association for Healthcare Resource and Materials ... 5-11. This week is dedicated to acknowledging and celebrating ... healthcare and the overall success of the healthcare supply chain. ... ...
... System To Reduce Claim Fraud and Costs by ... ILOG(R) (Nasdaq:,ILOG, Euronext: ILO, ISIN: FR0004042364) today announced ... in Argentina, is using ILOG,JRules(R) to automate its ... Swiss Medical has been able to reduce,unnecessary medical ...
... often seasonal allergy that affects between 10 and 20 ... a course of patient-adjusted dosing, according to new research ... Head and Neck Surgery. , During the ... allergic rhinitis, was observed in 69 patients, who were ...
... than 1 million children, Stores raise funds for Vitamin ... Quarters found in the,bottom of purses, pockets, and even on ... needy children. The Vitamin Shoppe is asking,everyone to donate their ... a,child., Affecting up to 140 million children every year, ...
Cached Medicine News:Health News:Broadlane Recognizes AHRMM National Healthcare Resource and Materials Management Week 2Health News:Broadlane Recognizes AHRMM National Healthcare Resource and Materials Management Week 3Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 2Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 3Health News:Hay fever may be best treated with self-adjusted dosing 2Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Antibody (IgG) Test is a semiquantitative enzyme ... significant IgG antibodies to M. pneumoniae between ... test should not be used for specimens ... (IgM) Test and is not intended for ...
... Test is a qualitative enzyme immunoassay ... Epstein-Barr virus capsid antigen (EBV-VCA), Epstein-Barr ... and Toxoplasma. When used in conjunction ... aid in the serodiagnosis of infectious ...
... Test is an enzyme immunoassay ... the presence of antibodies to ... and herpes simplex virus in ... to indicate previous or current ...
Medicine Products: